Citi tells investors it's time to sell Moderna after 600%-plus stock gains
Merck & Co Inc MRK
News
Merck in License Pact Worth Up to $2.13 Billion With SciBrunch Therapeutics — Update
Merck in License Pact Worth Up to $2.13 Billion With SciBrunch Therapeutics
Merck, Daiichi Sankyo Withdraw Application for Accelerated Approval of Lung Cancer Treatment
Merck, Eisai Get FDA OK of Welireg/Lenvima Combo in Kidney Cancer
Merck Phase 2b/3 Trial for Remigromig Meets Primary Endpoint
Moderna will reveal the data for its mRNA cancer vaccine next month. Here's why it matters.
Moderna's personalized mRNA shot could reshape the fight against skin cancer - but it may also be overhyped
Moderna's cancer-vaccine breakthrough drives broad biopharma stock rally
Moderna's experimental vaccine prevents cancer recurrence, in 'historic' win for personalized medicine. Its stock soared.
Moderna Moves Back Toward Covid-Era Valuation With Latest mRNA Update
Merck Up Over 9%, on Track for Record High Close — Data Talk
Moderna, Merck Shares Rally After Trial Shows Vaccine Success in Preventing Melanoma From Returning
Merck on Track for Record High Close — Data Talk
Merck On Pace for Record High Close — Data Talk
Merck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom Line
Merck & Co. on Track for Record High Close — Data Talk
Merck, Pfizer, Astellas Bladder Cancer Treatment Approved by FDA
Merck's Tulisokibart Hits Key Goals in Phase 3 Ulcerative Colitis Study
Merck Wins FDA Approvals for Keytruda Combination in Kidney Cancer
United States